Burning Rock revenue decreases 9.3% year over year in Q2
- Burning Rock Biotech (NASDAQ:BNR) reported second-quarter 2026 revenue of RMB134.7 million, down 9.3% year over year.
- The company’s net loss widened to RMB18.4 million, while gross margin remained stable at 72.6%.
- Several next-generation sequencing kits entered review procedures in China, including CMDE Priority Review or Special Review processes.
Burning Rock Biotech (NASDAQ:BNR) reported second-quarter 2026 revenue of RMB134.7 million, down 9.3% year over year, with net loss increasing to RMB18.4 million.
The decline was driven by lower central laboratory revenue of RMB36.8 million and pharma R&D revenue of RMB30.8 million, while in-hospital revenue increased 7.4% to RMB67.1 million.
Gross profit decreased 9.5% to RMB97.8 million, while gross margin remained broadly stable at 72.6%, with in-hospital gross margin improving to 77.1% and pharma R&D margin declining to 47.2%.
Operating expenses declined 3.2% to RMB115.8 million as research and development spending fell 37.3%, partially offset by higher selling, marketing, and general administrative expenses.
Burning Rock ended the quarter with RMB419.1 million in cash, cash equivalents, and restricted cash, while several NGS kits progressed through regulatory review procedures in China.
